AP
SRPT icon

Atwood & Palmer’s Sarepta Therapeutics SRPT Stock Holding History

Atwood & Palmer’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.5K Hold
1,400
– – ﹤0.01% 323
2026
Q2 		$25.2K Hold
1,400
– – ﹤0.01% 307
2026
Q1 		$30.5K Hold
1,400
– – ﹤0.01% 283
2025
Q4 		$30.1K Hold
1,400
– – ﹤0.01% 283
2025
Q3 		$27K Hold
1,400
– – ﹤0.01% 306
2025
Q2 		$23.9K Hold
1,400
– – ﹤0.01% 304
2025
Q1 		$89.3K Hold
1,400
– – 0.01% 188
2024
Q4 		$170K Hold
1,400
– – 0.01% 152
2024
Q3 		$175K Hold
1,400
– – 0.01% 154
2024
Q2 		$221K Sell
1,400
-1,600
-53% -$206K 0.02% 137
2024
Q1 		$388K Sell
3,000
-2,194
-42% -$269K 0.03% 119
2023
Q4 		$501K Sell
5,194
-5,353
-51% -$514K 0.04% 106
2023
Q3 		$1.28M Hold
10,547
– – 0.11% 69
2023
Q2 		$1.21M Buy
+10,547
New +$1.36M 0.11% 78

Other funds holding SRPT

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAFA
MJT & Associates Financial Advisory Monteviceo, Minnesota $155M AUM 15.7% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Atwood & Palmer's SRPT Position: Q3 2026 in Review

Atwood & Palmer held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 1,400 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #323.

Atwood & Palmer first reported a position in SRPT in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.28M in Q3 2023. 9 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Atwood & Palmer held 1,400 shares of Sarepta Therapeutics worth $25.5K as of Q3 2026.
  • Atwood & Palmer left its Sarepta Therapeutics share count unchanged in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Atwood & Palmer's portfolio in Q3 2026, its #323 holding.
  • Atwood & Palmer first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • Atwood & Palmer's Sarepta Therapeutics position peaked at $1.28M in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Atwood & Palmer's 13F filing for Q3 2026, filed 8 Oct 2026.